Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026

The Nasdaq Just Hit Correction Territory. History Says the Stock Market Will Do This Next (Hint: It May Shock You).

View original at nasdaq.com
The Nasdaq Just Hit Correction Territory. History Says the Stock Market Will Do This Next (Hint: It May Shock You). The U.S. stock market has stumbled in recent weeks as the Trump administration imposed tariffs on goods imported from Canada, China, and Mexico, potentially starting a trade war…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The tariffs proposed by the Trump administration would increase the average tax on U.S. imports to 13.8%, the highest level since 1939

    60% confidence

  • The current drawdown is a buying opportunity

    60% confidence

  • Stock Advisor service has more than quadrupled the return of S&P 500 since 2002

    60% confidence

  • Since 2010, the Nasdaq has returned an average of 21% during the 12-month period following its first close in correction territory

    60% confidence

  • The Nasdaq Composite has recovered from every correction and there is no reason to believe this one will be different

    60% confidence

  • The Nasdaq has historically bounced back very quickly from corrections

    60% confidence

  • The market dislikes uncertainty

    60% confidence

  • Tariffs probably hurt corporate earnings

    60% confidence

  • Businesses can either absorb the cost increases or pass them to buyers. Margins fall in the first scenario, and sales likely fall in the second scenario

    60% confidence

Data points we hold from this source

Stock Advisor · return vs sp5004 multiple
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
The Nasdaq Just Hit Correction Territory. History Says the Stock Market Will Do This Next (Hint: It May Shock You). — Source | Via News | ViaNews Market